Patent · US Active

Imidazopyridazinecarbonitriles useful as kinase inhibitors

US8252795B2 · kind B2 · utility

16Cited by

0References

11Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Brian E. Fink · Yardley, US
Libing Chen · Newtown, US
Ashvinikumar V. Gavai · Princeton Junction, US
Liqi He · West Chester, US
Soong-Hoon Kim · Titusville, US
Andrew James Nation · Scotch Plains, US
Yufen Zhao · Pennington, US
Litai H. Zhang · Lawrenceville, US

Key dates

Filing date	Oct 8, 2009
Grant date	Aug 28, 2012
Priority date	—
Expiry date	Apr 28, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides compounds of Formula (I)and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.